Miconazole is a synthetic imidazole antifungal agent used topically for the treatment of superficial fungal infections. In the 2% w/w concentration, it is primarily formulated as creams, gels, powders, and sprays for cutaneous application. It exhibits broad-spectrum fungistatic and fungicidal activity against dermatophytes (Trichophyton, Microsporum, Epidermophyton), yeasts (Candida albicans, Malassezia furfur), and other fungi. Its mechanism involves inhibition of ergosterol synthesis, a critical component of fungal cell membranes.
Adult: Apply a thin layer to the affected and surrounding skin area twice daily (morning and evening). For cream/gel: Gently rub in. For powder/spray: Apply a light covering.
Note: 1. Wash and dry the affected area thoroughly before application. 2. Apply a thin layer and rub gently. 3. Wash hands after application unless hands are being treated. 4. For intertriginous areas (skin folds), use sparingly to avoid maceration. 5. Treatment should typically continue for 2 weeks for dermatophytosis and at least 1 week after symptoms clear to prevent relapse. For pityriasis versicolor, treatment for 2-4 weeks is common.
Miconazole inhibits the fungal cytochrome P450 enzyme 14α-demethylase. This enzyme is crucial for converting lanosterol to ergosterol, the principal sterol component of the fungal cell membrane. Inhibition leads to depletion of ergosterol and accumulation of toxic methylated sterols, disrupting membrane structure and function. This results in increased membrane permeability, leakage of cellular contents, and inhibition of fungal growth.
Pregnancy: Category C (US FDA). Topical miconazole is considered safe for use during pregnancy as systemic absorption is minimal. However, it should be used only if clearly needed, on the smallest area necessary, and for the shortest duration. Oral gel should be avoided unless benefits outweigh risks.
Driving: No effect on driving ability.
| Warfarin and other Coumarin anticoagulants | Miconazole (especially oral gel) can potentiate anticoagulant effect, increasing INR and risk of bleeding. | Major |
| Oral Hypoglycemics (e.g., Glipizide, Tolbutamide) | May potentiate hypoglycemic effect. | Moderate |
| Phenytoin | May increase phenytoin serum levels, leading to toxicity. | Moderate |
| Cyclosporine, Tacrolimus | May increase levels of these immunosuppressants, increasing risk of nephrotoxicity and neurotoxicity. | Moderate |
| Simvastatin, Lovastatin | Increased risk of myopathy/rhabdomyolysis due to CYP3A4 inhibition. | Moderate |
Same composition (Miconazole (2% w/w)), different brands: